Attached files
| file | filename |
|---|---|
| 8-K - Emmaus Life Sciences, Inc. | v190323_8-k.htm |
| EX-4.1 - Emmaus Life Sciences, Inc. | v190323_ex4-1.htm |
| EX-4.2 - Emmaus Life Sciences, Inc. | v190323_ex4-2.htm |
|
|
Investors:
Marty Tullio, Managing
Partner
McCloud Communications,
LLC
949.553.9748
marty@mccloudcommunications.com
Media:
Chris Stern
Washington Media
Group
202-628-1280
cstern@washingtonmedia.com
Referenced–EEG (rEEG®) Shows Significant Improvement in
Pharmacotherapy, According to Journal of
Psychiatric
Research Article
Journal of
Psychiatric Research:
rEEG® Significantly Improves Successful Outcomes
for Treatment-Resistant Patients Suffering From
Depression
ALISO
VIEJO, CA - July 7,
2010 – CNS Response
(OTCBB:CNSO) today announced that physicians using Referenced-EEG
(rEEG®) had “success” rates reaching 65
percent
for patients with treatment-resistant depression, according to an article
published today in the Journal
of Psychiatric Research.
Referenced-EEG showed “significant improvement’’ in informing pharmacotherapy for
treatment-resistant patients in a 12-week study, according to the Journal of
Psychiatric Research
article. The study, conducted at 12 medical sites including Harvard, Stanford
and Cornell, shows that rEEG can provide important information for patients who
have failed first-line treatment.
The difference, or
separation, between rEEG and the control groups was 50 and 101 percent for the
study’s two primary
endpoints. Commonly, separation between a new treatment and a control group
falls below 10 percent in antidepressant studies.
Referenced-EEG, developed by CNS Response, Inc., is a
patented system that analyzes an individual patient’s brain waves against an extensive
patient outcomes database. By reducing guesswork, rEEG offers the potential to
curtail needless treatment delays and adverse drug reactions from ineffective
therapies.
The journal article concludes that rEEG
“would represent an easy,
relatively inexpensive, predictive, objective office procedure that builds upon
clinical judgment...’’
To read the full study, go to
www.cnsresponse.com
Personalized
Medicine
In all other fields of medicine, there
are tools deemed critical to finding effective treatment for individual
patients. There are, to name only a few, blood tests, x-rays, MRIs, and
many other ways of getting
physiological information from patients. Experts have long hoped that
"personalized medicine" – a way to identify the right medications
for the right patients – would offer something for
psychiatry.
- more -
Referenced–EEG (rEEG®) Shows Significant Improvement in
Pharmacotherapy, According to Journal of
Psychiatric Research Article
Page 2
Recent studies confirm the need: a
clinical trial called STAR*D with 4,000 subjects, the largest study ever
conducted evaluating pharmacotherapy for depression, was designed to provide
guidance in selecting the best "next step" treatment. It reported in 2006 that
after failing their third medication, most patients (55 percent) either dropped out or relapsed, and
80 percent of those who exited had not improved at the time of their exit.
After the first two medications, the study could offer no predictions beyond
"trial and error" as to which medications might work on any given patient. The
study published today by the Journal of
Psychiatric Research on
rEEG showed significant improvements over the Star*D trial.
The Need for
rEEG
Depression is a devastating,
debilitating condition. One in three people with depression fail to improve with
standard antidepressant therapy. On average these sufferers spend 10 years finding the right doctor and
medicine and $8,500 more per year on health care than those with ordinary
depression. They log more time in hospitals and more time in recovery.
Depression costs U.S. employers $83 billion annually and is a
major problem in the
military for those returning from combat.
Referenced-EEG is a novel assessment
tool that helps physicians understand the unique brain function of each patient, as measured
by EEG electrophysiology. EEG or electroencephalography is a
painless, non-invasive
20-minute procedure, which measures brain activity at specific points. That
information is processed and then compared to CNS Response’s reference database, which generates a
report doctors can use in evaluating treatment options. In 12 previous studies – and in use by practicing physicians
– doctors report better results than trial
and error.
To view the Journal of Psychiatric
Research article on rEEG visit www.cnsresponse.com
The
rEEG®
Study
The study was co-authored by Dr. Charles
DeBattista, Stanford University School of Medicine, Dr. Gustavo Kinrys,
Cambridge Health Alliance, Dr. Daniel Hoffman, CNS Response Inc., Dr. Corey
Goldstein, Rush University Medical Center, Dr. John Zajecka, Rush
University Medical Center,
Dr. James Kocsis, New York Presbyterian Hospital, Dr. Martin Teicher, Harvard
Medical School, Dr. Steven Potkin, UCI School of Medicine, Dr. Adrian Preda, UCI
School of Medicine, Dr. Gurmeet Multani, Shanti Clinical Trials, Dr. Mark
Schiller, Mind Therapy Clinic, Dr. Dan
Iosifescu, Massachusetts General Hospital, and Dr. Maurizio Fava, Massachusetts
General Hospital.
About CNS
Response
Today, most physicians are able to base
treatment on objective test data, such as EKGs, MRIs, blood tests, etc. Broadly speaking, such
advances have not yet come to those physicians practicing
psychiatry.
Referenced-EEG was developed by
physicians to provide objective, personalized, statistical data on patient
neurophysiology. In clinical trials, physicians using rEEG data have consistently achieved superior clinical
results compared to physicians using Trial and Error
pharmacotherapy.
- more -
Referenced–EEG (rEEG®) Shows Significant Improvement in
Pharmacotherapy, According to Journal of
Psychiatric Research Article
Page 3
To read more about the benefits this
patented technology provides physicians, patients and insurers, please visit the
CNS Response website, www.cnsresponse.com.
Safe Harbor
Statement Under the
Private Securities Litigation Reform Act of 1995
Except for the historical information
contained herein, the matters discussed are forward-looking statements made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995, as
amended. These forward-looking statements involve risks and uncertainties as set
forth in the Company's filings with the Securities and Exchange Commission.
These risks and uncertainties could cause actual results to differ materially
from any forward-looking statements made
herein.
###